Infliximab-induced intertriginous psoriasis in patient with Crohn's disease.
Tumor necrosis factor-α (TNFα) inhibition is an effective treatment of moderate-to-severe psoriasis and other diseases (rheumatoid arthritis, ankylosing spondylitis, psoriasis or Crohn's disease). We report a case of a 32-years-old patient affected by Crohn's disease since the age of 25 who started infliximab infusion after four years of treatment with prednisone and azathioprine per os without improvement. After the fifth infusion of infliximab, he developed a form of intertriginous psoriasis which was approached with topical steroid cream. The patient never presented psoriasis in the past. New onset of psoriasis in patients without history for skin diseases (as in our case) is a quite uncommon complication of TNFα inhibitor therapy. The increased production of IFNα during TNFα inhibitor therapy is a possible pathophysiologic explanation for this paradoxical effect of the anti-TNFα.
Department of Dermatology, Circolo Hospital and Macchi Foundation, Varese, Italy.
Federica
F
Mola
Department of Dermatology, Circolo Hospital and Macchi Foundation, Varese, Italy.
Alberico
A
Motolese
crohn's disease.; psoriasis; tumor necrosis factor-α